ACLY and neoplasm: SB-204990 was found to abolish the promoting effect of Cullin3 downregulation on lipid synthesis, cell proliferation, and tumor growth, suggesting that targeting ACLY could be a potential therapeutic strategy for lung cancer with reduced expression of Cullin3 [86].